Meta‐analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication

Summary Background Several randomized‐controlled trials (RCTs) have sought to determine the efficacy of bovine lactoferrin in Helicobacter pylori eradication with equivocal results. Aim To evaluate the effect of bovine lactoferrin supplementation in H. pylori eradication. Methods Electronic datab...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Alimentary pharmacology & therapeutics Jg. 29; H. 7; S. 720 - 730
Hauptverfasser:	SACHDEVA, A., NAGPAL, J.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Oxford, UK Blackwell Publishing Ltd 01.04.2009 Blackwell
Schlagworte:	Anti-Bacterial Agents - therapeutic use Bacterial diseases Bacterial diseases of the digestive system and abdomen Biological and medical sciences Dietary Supplements Digestive system Gastroenterology. Liver. Pancreas. Abdomen Helicobacter Infections - drug therapy Helicobacter pylori Helicobacter pylori - drug effects Human bacterial diseases Humans Infectious diseases Lactoferrin - therapeutic use Medical sciences Pharmacology. Drug treatments Randomized Controlled Trials as Topic Spirillales Bovine Treatment efficiency Spirillaceae Ox Eradication Metaanalysis Infection Vertebrata Lactoferrin Mammalia Helicobacter pylori Animal Bacteriosis Bacteria Artiodactyla Ungulata
ISSN:	0269-2813, 1365-2036, 1365-2036
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Summary Background Several randomized‐controlled trials (RCTs) have sought to determine the efficacy of bovine lactoferrin in Helicobacter pylori eradication with equivocal results. Aim To evaluate the effect of bovine lactoferrin supplementation in H. pylori eradication. Methods Electronic databases, reviews, bibliographies, s and conference proceedings were searched. Included trials had to be randomized or quasi‐randomized and controlled, using bovine lactoferrin in the intervention group, treating Helicobacter‐infected subjects and evaluating eradication of H. pylori as an outcome. Results The search identified five eligible RCTs (of 169). Data were available for 682 subjects (bovine lactoferrin group‐n = 316; control group‐n = 366). The pooled odds ratio (five studies) for eradication by intention‐to‐treat analysis was 2.22 (95% CI 1.44–3.44; P = 0.0003) using the fixed effects model (FEM) and 2.24 (95% CI 1.15–4.35; P = 0.0003) using the random effects model (REM) (Cochran’s Q = 6.83; P = 0.145). The pooled risk difference was 0.11 (95% CI 0.05–0.16; P = 0.0001) by FEM (Cochran’s Q = 6.67; P = 0.154) and 0.10 (95% CI 0.04–0.17; P = 0.0023) by REM. There was no significant difference in incidence of adverse effects. Conclusion Bovine lactoferrin potentially improves H. pylori eradication rates without any impact on adverse effects, but available evidence is limited and further research is necessary to confirm the findings.
AbstractList	Summary Background Several randomized‐controlled trials (RCTs) have sought to determine the efficacy of bovine lactoferrin in Helicobacter pylori eradication with equivocal results. Aim To evaluate the effect of bovine lactoferrin supplementation in H. pylori eradication. Methods Electronic databases, reviews, bibliographies, s and conference proceedings were searched. Included trials had to be randomized or quasi‐randomized and controlled, using bovine lactoferrin in the intervention group, treating Helicobacter‐infected subjects and evaluating eradication of H. pylori as an outcome. Results The search identified five eligible RCTs (of 169). Data were available for 682 subjects (bovine lactoferrin group‐n = 316; control group‐n = 366). The pooled odds ratio (five studies) for eradication by intention‐to‐treat analysis was 2.22 (95% CI 1.44–3.44; P = 0.0003) using the fixed effects model (FEM) and 2.24 (95% CI 1.15–4.35; P = 0.0003) using the random effects model (REM) (Cochran’s Q = 6.83; P = 0.145). The pooled risk difference was 0.11 (95% CI 0.05–0.16; P = 0.0001) by FEM (Cochran’s Q = 6.67; P = 0.154) and 0.10 (95% CI 0.04–0.17; P = 0.0023) by REM. There was no significant difference in incidence of adverse effects. Conclusion Bovine lactoferrin potentially improves H. pylori eradication rates without any impact on adverse effects, but available evidence is limited and further research is necessary to confirm the findings. Background Several randomized‐controlled trials (RCTs) have sought to determine the efficacy of bovine lactoferrin in Helicobacter pylori eradication with equivocal results. Aim To evaluate the effect of bovine lactoferrin supplementation in H. pylori eradication. Methods Electronic databases, reviews, bibliographies, abstracts and conference proceedings were searched. Included trials had to be randomized or quasi‐randomized and controlled, using bovine lactoferrin in the intervention group, treating Helicobacter ‐infected subjects and evaluating eradication of H. pylori as an outcome. Results The search identified five eligible RCTs (of 169). Data were available for 682 subjects (bovine lactoferrin group‐ n = 316; control group‐ n = 366). The pooled odds ratio (five studies) for eradication by intention‐to‐treat analysis was 2.22 (95% CI 1.44–3.44; P = 0.0003) using the fixed effects model (FEM) and 2.24 (95% CI 1.15–4.35; P = 0.0003) using the random effects model (REM) (Cochran’s Q = 6.83; P = 0.145). The pooled risk difference was 0.11 (95% CI 0.05–0.16; P = 0.0001) by FEM (Cochran’s Q = 6.67; P = 0.154) and 0.10 (95% CI 0.04–0.17; P = 0.0023) by REM. There was no significant difference in incidence of adverse effects. Conclusion Bovine lactoferrin potentially improves H. pylori eradication rates without any impact on adverse effects, but available evidence is limited and further research is necessary to confirm the findings. Several randomized-controlled trials (RCTs) have sought to determine the efficacy of bovine lactoferrin in Helicobacter pylori eradication with equivocal results. To evaluate the effect of bovine lactoferrin supplementation in H. pylori eradication. Electronic databases, reviews, bibliographies, abstracts and conference proceedings were searched. Included trials had to be randomized or quasi-randomized and controlled, using bovine lactoferrin in the intervention group, treating Helicobacter-infected subjects and evaluating eradication of H. pylori as an outcome. The search identified five eligible RCTs (of 169). Data were available for 682 subjects (bovine lactoferrin group-n = 316; control group-n = 366). The pooled odds ratio (five studies) for eradication by intention-to-treat analysis was 2.22 (95% CI 1.44-3.44; P = 0.0003) using the fixed effects model (FEM) and 2.24 (95% CI 1.15-4.35; P = 0.0003) using the random effects model (REM) (Cochran's Q = 6.83; P = 0.145). The pooled risk difference was 0.11 (95% CI 0.05-0.16; P = 0.0001) by FEM (Cochran's Q = 6.67; P = 0.154) and 0.10 (95% CI 0.04-0.17; P = 0.0023) by REM. There was no significant difference in incidence of adverse effects. Bovine lactoferrin potentially improves H. pylori eradication rates without any impact on adverse effects, but available evidence is limited and further research is necessary to confirm the findings. SummaryBackgroundSeveral randomized-controlled trials (RCTs) have sought to determine the efficacy of bovine lactoferrin in Helicobacter pylori eradication with equivocal results.AimTo evaluate the effect of bovine lactoferrin supplementation in H. pylori eradication.MethodsElectronic databases, reviews, bibliographies, abstracts and conference proceedings were searched. Included trials had to be randomized or quasi-randomized and controlled, using bovine lactoferrin in the intervention group, treating Helicobacter-infected subjects and evaluating eradication of H. pylori as an outcome.ResultsThe search identified five eligible RCTs (of 169). Data were available for 682 subjects (bovine lactoferrin group-n=316; control group-n=366). The pooled odds ratio (five studies) for eradication by intention-to-treat analysis was 2.22 (95% CI 1.44-3.44; P=0.0003) using the fixed effects model (FEM) and 2.24 (95% CI 1.15-4.35; P=0.0003) using the random effects model (REM) (Cochran's Q=6.83; P=0.145). The pooled risk difference was 0.11 (95% CI 0.05-0.16; P=0.0001) by FEM (Cochran's Q=6.67; P=0.154) and 0.10 (95% CI 0.04-0.17; P=0.0023) by REM. There was no significant difference in incidence of adverse effects.ConclusionBovine lactoferrin potentially improves H. pylori eradication rates without any impact on adverse effects, but available evidence is limited and further research is necessary to confirm the findings. Several randomized-controlled trials (RCTs) have sought to determine the efficacy of bovine lactoferrin in Helicobacter pylori eradication with equivocal results.BACKGROUNDSeveral randomized-controlled trials (RCTs) have sought to determine the efficacy of bovine lactoferrin in Helicobacter pylori eradication with equivocal results.To evaluate the effect of bovine lactoferrin supplementation in H. pylori eradication.AIMTo evaluate the effect of bovine lactoferrin supplementation in H. pylori eradication.Electronic databases, reviews, bibliographies, abstracts and conference proceedings were searched. Included trials had to be randomized or quasi-randomized and controlled, using bovine lactoferrin in the intervention group, treating Helicobacter-infected subjects and evaluating eradication of H. pylori as an outcome.METHODSElectronic databases, reviews, bibliographies, abstracts and conference proceedings were searched. Included trials had to be randomized or quasi-randomized and controlled, using bovine lactoferrin in the intervention group, treating Helicobacter-infected subjects and evaluating eradication of H. pylori as an outcome.The search identified five eligible RCTs (of 169). Data were available for 682 subjects (bovine lactoferrin group-n = 316; control group-n = 366). The pooled odds ratio (five studies) for eradication by intention-to-treat analysis was 2.22 (95% CI 1.44-3.44; P = 0.0003) using the fixed effects model (FEM) and 2.24 (95% CI 1.15-4.35; P = 0.0003) using the random effects model (REM) (Cochran's Q = 6.83; P = 0.145). The pooled risk difference was 0.11 (95% CI 0.05-0.16; P = 0.0001) by FEM (Cochran's Q = 6.67; P = 0.154) and 0.10 (95% CI 0.04-0.17; P = 0.0023) by REM. There was no significant difference in incidence of adverse effects.RESULTSThe search identified five eligible RCTs (of 169). Data were available for 682 subjects (bovine lactoferrin group-n = 316; control group-n = 366). The pooled odds ratio (five studies) for eradication by intention-to-treat analysis was 2.22 (95% CI 1.44-3.44; P = 0.0003) using the fixed effects model (FEM) and 2.24 (95% CI 1.15-4.35; P = 0.0003) using the random effects model (REM) (Cochran's Q = 6.83; P = 0.145). The pooled risk difference was 0.11 (95% CI 0.05-0.16; P = 0.0001) by FEM (Cochran's Q = 6.67; P = 0.154) and 0.10 (95% CI 0.04-0.17; P = 0.0023) by REM. There was no significant difference in incidence of adverse effects.Bovine lactoferrin potentially improves H. pylori eradication rates without any impact on adverse effects, but available evidence is limited and further research is necessary to confirm the findings.CONCLUSIONBovine lactoferrin potentially improves H. pylori eradication rates without any impact on adverse effects, but available evidence is limited and further research is necessary to confirm the findings.
Author	SACHDEVA, A. NAGPAL, J.
Author_xml	– sequence: 1 givenname: A. surname: SACHDEVA fullname: SACHDEVA, A. – sequence: 2 givenname: J. surname: NAGPAL fullname: NAGPAL, J.
BackLink	http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21218504$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/19183156$$D View this record in MEDLINE/PubMed
BookMark	eNqNkc1u1DAUhS3Uik4HXgFlA6wSrn_iJEggVRVQpFYgVNaW49xIHnniwc5As-sj9Bl5EpzOMIsuKJYlW_Z3jo7uOSVHgx-QkIxCQdN6syool2XOgMuCATQF8IaL4uYJWRw-jsgCmGxyVlN-Qk5jXAGArIA9JSe0oTWnpVyQb1c46t-3d3rQboo2vs2w763RZsp8n7X-px0wc9qMvscQ7JClfYHOGt-mRwzZZnI-2AyD7pJstH54Ro577SI-359L8v3jh-vzi_zyy6fP52eXuRFVI_JWlhSw6TirU5a27mpTm4oalH1biUZTIUrNIEWRTasbA0Z0rJTYcdFJ3lV8SV7vfDfB_9hiHNXaRoPO6QH9NqqKc85AJvclefVPkkEpUhhI4Is9uG3X2KlNsGsdJvV3Xgl4uQd0NNr1QQ_GxgPHKKN1CSJx73ecCT7GgL0ydryfzhi0dYqCmotUKzX3pea-1Fykui9S3SSD-oHBIcvj0nc76S_rcPpvnTr7ej3f-B_VfrUO
CitedBy_id	crossref_primary_10_3390_pathogens12040599 crossref_primary_10_1016_j_gastre_2016_11_007 crossref_primary_10_1016_j_gtc_2015_05_005 crossref_primary_10_3390_nu15061394 crossref_primary_10_1016_j_gtc_2015_05_004 crossref_primary_10_1016_j_gastrohep_2013_01_011 crossref_primary_10_3892_ijmm_2015_2251 crossref_primary_10_1016_j_pop_2011_05_001 crossref_primary_10_1002_jsfa_11708 crossref_primary_10_1517_14656566_2013_763926 crossref_primary_10_1139_bcb_2016_0073 crossref_primary_10_3748_wjg_v20_i36_12781 crossref_primary_10_1093_jac_dky510 crossref_primary_10_1093_advances_nmac047 crossref_primary_10_1111_hel_12572 crossref_primary_10_3748_wjg_v20_i30_10338 crossref_primary_10_1097_MCG_0000000000000318 crossref_primary_10_1080_10408398_2024_2436139 crossref_primary_10_1016_j_gastrohep_2016_05_003 crossref_primary_10_3390_diseases12120311 crossref_primary_10_1080_1028415X_2020_1760532 crossref_primary_10_1111_hel_12529 crossref_primary_10_1371_journal_pone_0268537
Cites_doi	10.1097/00004836-200305000-00003 10.1097/01.mpg.0000243435.54958.68 10.1093/jn/131.8.2101 10.3109/00365529309098341 10.1128/IAI.67.7.3267-3275.1999 10.1128/IAI.67.3.1353-1358.1999 10.1046/j.1365-2036.2002.0160s1003.x 10.1097/00004836-200305000-00006 10.1111/j.1572-0241.2002.07063.x 10.1016/0167-5699(95)80016-6 10.1111/j.1365-2036.2005.02448.x 10.1046/j.1365-2036.2000.00885.x 10.1159/000051865 10.1016/S0021-9258(17)31566-1 10.1016/j.clinthera.2006.11.011 10.1007/s10156-005-0407-X 10.1111/j.1523-5378.2007.00497.x 10.1358/mf.2005.27.5.896760 10.1111/j.1523-5378.2007.00538.x 10.1046/j.1365-2036.2003.01395.x 10.1111/j.1365-2036.2004.02274.x 10.1080/00365529950173627 10.3168/jds.S0022-0302(04)73549-3 10.1111/j.1365-2036.2006.02851.x 10.1016/j.dld.2005.01.017 10.1007/BF02490180 10.1111/j.1365-2672.1994.tb03065.x 10.1111/j.1365-2036.2006.03179.x 10.1111/j.1572-0241.2007.01514_1.x 10.7326/ACPJC-2006-145-2-049 10.1046/j.1365-2036.2001.00923.x 10.1023/A:1026675916421 10.1016/j.dld.2007.05.021 10.1002/9780470693926.ch5 10.1016/S1590-8658(03)00409-2 10.1111/j.1572-0241.2007.01085.x
ContentType	Journal Article
Copyright	2009 Blackwell Publishing Ltd 2009 INIST-CNRS
Copyright_xml	– notice: 2009 Blackwell Publishing Ltd – notice: 2009 INIST-CNRS
DBID	AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7QL C1K 7X8
DOI	10.1111/j.1365-2036.2009.03934.x
DatabaseName	CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management MEDLINE - Academic
DatabaseTitleList	CrossRef MEDLINE Bacteriology Abstracts (Microbiology B) MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1365-2036
EndPage	730
ExternalDocumentID	19183156 21218504 10_1111_j_1365_2036_2009_03934_x APT3934
Genre	article Research Support, Non-U.S. Gov't Meta-Analysis Journal Article
GroupedDBID	--- .3N .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 23M 24P 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAKAS AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHEFC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF D-6 D-7 D-E D-F DC6 DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DTERQ E3Z EAD EAP EAS EBC EBD EBS EBX EJD EMB EMK EMOBN EST ESX EX3 F00 F01 F04 F5P FEDTE FIJ FUBAC FZ0 G-S G.N GODZA GX1 H.X HF~ HGLYW HVGLF HZI HZ~ IHE IPNFZ IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK0 MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D P6G PALCI Q.N Q11 QB0 Q~Q R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TR2 TUS UB1 V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 YOC ZZTAW ~IA ~WT AAMMB AAYXX AEFGJ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY AIQQE CITATION O8X IQODW CGR CUY CVF ECM EIF NPM 7QL C1K 7X8
ID	FETCH-LOGICAL-c4794-b6510e9d328831b8d8c8c71ce6fb749a1445a20cac69ba9c0c4d256ed34d63d73
IEDL.DBID	DRFUL
ISICitedReferencesCount	39
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000263908900003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0269-2813 1365-2036
IngestDate	Thu Jul 10 22:52:57 EDT 2025 Tue Oct 07 09:22:22 EDT 2025 Mon Jul 21 05:46:29 EDT 2025 Mon Jul 21 09:15:56 EDT 2025 Sat Nov 29 01:38:46 EST 2025 Tue Nov 18 22:10:13 EST 2025 Wed Jan 22 16:25:19 EST 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	7
Keywords	Spirillales Bovine Treatment efficiency Spirillaceae Ox Eradication Metaanalysis Infection Vertebrata Lactoferrin Mammalia Helicobacter pylori Animal Bacteriosis Bacteria Artiodactyla Ungulata
Language	English
License	http://onlinelibrary.wiley.com/termsAndConditions#vor CC BY 4.0
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c4794-b6510e9d328831b8d8c8c71ce6fb749a1445a20cac69ba9c0c4d256ed34d63d73
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2036.2009.03934.x
PMID	19183156
PQID	20545100
PQPubID	23462
PageCount	11
ParticipantIDs	proquest_miscellaneous_733320688 proquest_miscellaneous_20545100 pubmed_primary_19183156 pascalfrancis_primary_21218504 crossref_citationtrail_10_1111_j_1365_2036_2009_03934_x crossref_primary_10_1111_j_1365_2036_2009_03934_x wiley_primary_10_1111_j_1365_2036_2009_03934_x_APT3934
PublicationCentury	2000
PublicationDate	April 2009
PublicationDateYYYYMMDD	2009-04-01
PublicationDate_xml	– month: 04 year: 2009 text: April 2009
PublicationDecade	2000
PublicationPlace	Oxford, UK
PublicationPlace_xml	– name: Oxford, UK – name: Oxford – name: England
PublicationTitle	Alimentary pharmacology & therapeutics
PublicationTitleAlternate	Aliment Pharmacol Ther
PublicationYear	2009
Publisher	Blackwell Publishing Ltd Blackwell
Publisher_xml	– name: Blackwell Publishing Ltd – name: Blackwell
References	2002; 16 2004; 87 2007; 39 2007; 102 2004; 20 1995; 16 2002; 97 2004; 9 2003; 35 2004; 4 2003; 36 1999; 67 2006 2005; 21 2006; 1540 2003; 17 2005; 27 1997; 3 1998; 43 2007; 12 2007; 13 2001; 63 2003; 1389 2007; 1592 2001; 131 1994; 269 2001 2006; 23 2000; 14 2006; 28 2003; 8 1999; 34 1994; 77 1993; 196 2001; 15 2005; 37 2007; 44 2005; 11 2006; 145 2007; 25 2005; 14 Higgins JPT (e_1_2_6_10_2) 2006 Tursi A (e_1_2_6_15_2) 2007; 13 Cao YJ (e_1_2_6_44_2) 2005; 14 Cha n FK (e_1_2_6_17_2) 2006; 145 e_1_2_6_13_2 e_1_2_6_34_2 e_1_2_6_11_2 e_1_2_6_32_2 Mann DM (e_1_2_6_38_2) 1994; 269 e_1_2_6_36_2 e_1_2_6_41_2 Aragona G (e_1_2_6_24_2) 2003; 8 e_1_2_6_7_2 e_1_2_6_9_2 e_1_2_6_3_2 e_1_2_6_5_2 (e_1_2_6_20_2) 2006; 1540 e_1_2_6_47_2 e_1_2_6_49_2 e_1_2_6_28_2 e_1_2_6_26_2 e_1_2_6_45_2 e_1_2_6_50_2 e_1_2_6_31_2 Di Mario F (e_1_2_6_23_2) 2004; 9 (e_1_2_6_21_2) 2003; 1389 (e_1_2_6_18_2) 2007; 1592 Zhang GH (e_1_2_6_39_2) 1999; 67 Guo JB (e_1_2_6_43_2) 2004; 4 e_1_2_6_12_2 e_1_2_6_35_2 e_1_2_6_33_2 e_1_2_6_16_2 e_1_2_6_14_2 e_1_2_6_37_2 Imoto I (e_1_2_6_22_2) 2004; 9 e_1_2_6_42_2 e_1_2_6_40_2 Di Mario F (e_1_2_6_19_2) 2006; 145 e_1_2_6_8_2 e_1_2_6_29_2 e_1_2_6_4_2 e_1_2_6_6_2 e_1_2_6_48_2 e_1_2_6_2_2 e_1_2_6_27_2 e_1_2_6_25_2 Di Mario F (e_1_2_6_30_2) 2004; 9 e_1_2_6_46_2
References_xml	– volume: 16 start-page: 417 year: 1995 end-page: 9 article-title: Lactoferrin: a multifunctional immunoregulatory protein? publication-title: Immunol Today – volume: 27 start-page: 327 year: 2005 end-page: 9 article-title: In vivo tests of natural therapy, Tibetan yogurt or fresh broccoli, for infection publication-title: Methods Find Exp Clin Pharmacol – volume: 102 start-page: 951 year: 2007 end-page: 6 article-title: eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics publication-title: Am J Gastroenterol – volume: 39 start-page: 806 year: 2007 end-page: 10 article-title: eradication with either quadruple regimen with lactoferrin or levofloxacin‐based triple therapy: a multicentre study publication-title: Dig Liver Dis – volume: 12 start-page: 238 year: 2007 end-page: 43 article-title: A curcumin‐based 1‐week triple therapy for eradication of infection: something to learn from failure? publication-title: Helicobacter – volume: 14 start-page: 195 year: 2005 end-page: 9 article-title: Control of intestinal flora alteration induced by eradication therapy of infection in the elders publication-title: Chin J Gastroenterol Hepatol – volume: 37 start-page: 496 year: 2005 end-page: 500 article-title: Quadruple therapy with lactoferrin for eradication: a randomised, multicentre study publication-title: Dig Liver Dis – volume: 34 start-page: 238 year: 1999 end-page: 43 article-title: The therapeutic effect of bovine lactoferrin in the host infected with publication-title: Scand J Gastroenterol – volume: 9 start-page: 568 year: 2004 article-title: Efficacy of bovine lactoferrin for eradication: results of a multicenter study publication-title: Helicobacter – volume: 4 start-page: 163 year: 2004 end-page: 5 article-title: The application of clostridium to the eradication of publication-title: Chin J Celiopathy – volume: 87 start-page: 4073 year: 2004 end-page: 9 article-title: Suppressive effect of functional drinking yogurt containing specific egg yolk immunoglobulin on in humans publication-title: J Dairy Sci – volume: 43 start-page: 2750 year: 1998 end-page: 6 article-title: Antibiotic properties of bovine lactoferrin on publication-title: Dig Dis Sci – volume: 1592 start-page: 10 year: 2007 article-title: The addition of lactoferrin and probiotics to standard triple therapy may be beneficial in patients with infections publication-title: Inpharma Wkly – volume: 17 start-page: 125 year: 2003 end-page: 9 article-title: Human recombinant lactoferrin is ineffective in the treatment of human infection publication-title: Aliment Pharmacol Ther – volume: 145 start-page: 49 year: 2006 article-title: Bovine lactoferrin added to triple therapy increased eradication rate publication-title: ACP J Club – volume: 25 start-page: 155 year: 2007 end-page: 68 article-title: Meta‐analysis: the effect of supplementation with probiotics on eradication rates and adverse events during eradication therapy publication-title: Aliment Pharmacol Ther – volume: 14 start-page: 1625 year: 2000 end-page: 9 article-title: A lyophilized and inactivated culture of increases eradication rates publication-title: Aliment Pharmacol Ther – volume: 1540 start-page: 12 year: 2006 article-title: Adding bovine lactoferrin to triple therapy in patients with infection increases eradication rates publication-title: Inpharma Wkly – volume: 28 start-page: 1960 year: 2006 end-page: 6 article-title: Eradication of with triple therapy: an epidemiologic analysis of trends in Turkey over 10 years publication-title: Clin Ther – volume: 67 start-page: 3267 year: 1999 end-page: 75 article-title: Innate antimicrobial activity of nasal secretions publication-title: Infect Immun – volume: 145 start-page: 49 year: 2006 article-title: Bovine lactoferrin for eradication: an open, randomized, multicentre study publication-title: ACP J Club – volume: 63 start-page: 1 year: 2001 end-page: 7 article-title: Effect of Lactobacillus GG supplementation on antibiotic‐associated gastrointestinal side effects during eradication therapy: a pilot study publication-title: Digestion – volume: 97 start-page: 2744 year: 2002 end-page: 9 article-title: Effect of different probiotic preparations on anti‐ therapy‐related side effects: a parallel group, triple blind, placebo‐controlled study publication-title: Am J Gastroenterol – volume: 102 start-page: 2601 year: 2007 article-title: A quintuple therapy for eradication publication-title: Am J Gastroenterol – volume: 16 start-page: 3 issue: Suppl. 1 year: 2002 end-page: 15 article-title: Review article: natural history and epidemiology of infection publication-title: Aliment Pharmacol Ther – volume: 269 start-page: 23661 year: 1994 end-page: 7 article-title: Delineation of the glycosaminoglycan‐binding site in the human inflammatory response protein lactoferrin publication-title: J Biol Chem – volume: 20 start-page: 1181 year: 2004 end-page: 8 article-title: Bacillus clausii therapy to reduce side‐effects of anti‐ treatment: randomized, double‐blind, placebo controlled trial publication-title: Aliment Pharmacol Ther – volume: 1389 start-page: 10 year: 2003 article-title: Addition of bovine lactoferrin improves eradication publication-title: Inpharma Wkly – volume: 13 start-page: CR187 year: 2007 end-page: 90 article-title: Effect of lactoferrin supplementation on the effectiveness and tolerability of a 7‐day quadruple therapy after failure of a first attempt to cure infection publication-title: Med Sci Monit – volume: 3 start-page: 85 year: 1997 end-page: 9 article-title: Antibacterial effects of lactoferrin and a pepsin‐generated lactoferrin peptide against in vitro publication-title: J Infect Chemother – start-page: 87 year: 2001 end-page: 108 – volume: 12 start-page: 31 year: 2007 end-page: 7 article-title: Treatment of publication-title: Helicobacter – volume: 36 start-page: 396 year: 2003 end-page: 8 article-title: Use of lactoferrin for eradication: preliminary results publication-title: J Clin Gastroenterol – volume: 9 start-page: 576 year: 2004 end-page: 7 article-title: Suppressive effect of bovine lactoferrin against publication-title: Helicobacter – volume: 8 start-page: 463 year: 2003 article-title: Lactoferrin in a 1‐week triple therapy for eradication of publication-title: Helicobacter – volume: 36 start-page: 384 year: 2003 end-page: 5 article-title: Use of lactoferrin for eradication publication-title: J Clin Gastroenterol – volume: 44 start-page: 245 year: 2007 end-page: 51 article-title: A double‐blind, placebo‐controlled, pilot study of bovine lactoferrin supplementation in bottle‐fed infants publication-title: J Pediatr Gastroenterol Nutr – volume: 131 start-page: 2101 year: 2001 end-page: 4 article-title: Gastric digestion of bovine lactoferrin in vivo in adults publication-title: J Nutr – volume: 23 start-page: 1235 year: 2006 end-page: 40 article-title: Bovine lactoferrin for eradication: an open, randomized, multicentre study publication-title: Aliment Pharmacol Ther – start-page: 79 year: 2006 end-page: 91 – volume: 77 start-page: 208 year: 1994 end-page: 14 article-title: Lactoferricin, a new antimicrobial peptide publication-title: J Appl Bacteriol – volume: 196 start-page: 34 year: 1993 end-page: 7 article-title: Compliance, adverse events and antibiotic resistance in treatment publication-title: Scand J Gastroenterol Suppl – volume: 35 start-page: 706 year: 2003 end-page: 10 article-title: Use of bovine lactoferrin for eradication publication-title: Dig Liver Dis – volume: 11 start-page: 265 year: 2005 end-page: 9 article-title: Bovine lactoferrin is effective to suppress colonization in the human stomach: a randomized, double‐blind, placebo‐controlled study publication-title: J Infect Chemother – volume: 21 start-page: 1263 year: 2005 end-page: 72 article-title: Probiotic supplementation improves tolerance to eradication therapy‐‐a placebo‐controlled, double‐blind randomized pilot study publication-title: Aliment Pharmacol Ther – volume: 15 start-page: 163 year: 2001 end-page: 9 article-title: The effect of oral administration of Lactobacillus GG on antibiotic‐associated gastrointestinal side‐effects during eradication therapy publication-title: Aliment Pharmacol Ther – volume: 9 start-page: 569 year: 2004 end-page: 70 article-title: Bovine lactoferrin as rescue treatment for infection: results of a multicenter study publication-title: Helicobacter – volume: 67 start-page: 1353 year: 1999 end-page: 8 article-title: Neutralization of endotoxin in vitro and in vivo by a human lactoferrin‐derived peptide publication-title: Infect Immun – volume: 8 start-page: 463 year: 2003 ident: e_1_2_6_24_2 article-title: Lactoferrin in a 1‐week triple therapy for eradication of H. pylori publication-title: Helicobacter – volume: 9 start-page: 569 year: 2004 ident: e_1_2_6_30_2 article-title: Bovine lactoferrin as rescue treatment for Helicobacter pylori infection: results of a multicenter study publication-title: Helicobacter – ident: e_1_2_6_27_2 doi: 10.1097/00004836-200305000-00003 – ident: e_1_2_6_28_2 doi: 10.1097/01.mpg.0000243435.54958.68 – ident: e_1_2_6_35_2 doi: 10.1093/jn/131.8.2101 – ident: e_1_2_6_5_2 doi: 10.3109/00365529309098341 – ident: e_1_2_6_40_2 doi: 10.1128/IAI.67.7.3267-3275.1999 – volume: 67 start-page: 1353 year: 1999 ident: e_1_2_6_39_2 article-title: Neutralization of endotoxin in vitro and in vivo by a human lactoferrin‐derived peptide publication-title: Infect Immun doi: 10.1128/IAI.67.3.1353-1358.1999 – volume: 14 start-page: 195 year: 2005 ident: e_1_2_6_44_2 article-title: Control of intestinal flora alteration induced by eradication therapy of Helicobacter pylori infection in the elders publication-title: Chin J Gastroenterol Hepatol – ident: e_1_2_6_2_2 doi: 10.1046/j.1365-2036.2002.0160s1003.x – ident: e_1_2_6_25_2 doi: 10.1097/00004836-200305000-00006 – ident: e_1_2_6_48_2 doi: 10.1111/j.1572-0241.2002.07063.x – ident: e_1_2_6_37_2 doi: 10.1016/0167-5699(95)80016-6 – ident: e_1_2_6_49_2 doi: 10.1111/j.1365-2036.2005.02448.x – ident: e_1_2_6_50_2 doi: 10.1046/j.1365-2036.2000.00885.x – volume: 4 start-page: 163 year: 2004 ident: e_1_2_6_43_2 article-title: The application of clostridium to the eradication of Helicobacter pylori publication-title: Chin J Celiopathy – ident: e_1_2_6_47_2 doi: 10.1159/000051865 – volume: 1389 start-page: 10 year: 2003 ident: e_1_2_6_21_2 article-title: Addition of bovine lactoferrin improves H. pylori eradication publication-title: Inpharma Wkly – volume: 269 start-page: 23661 year: 1994 ident: e_1_2_6_38_2 article-title: Delineation of the glycosaminoglycan‐binding site in the human inflammatory response protein lactoferrin publication-title: J Biol Chem doi: 10.1016/S0021-9258(17)31566-1 – ident: e_1_2_6_3_2 doi: 10.1016/j.clinthera.2006.11.011 – start-page: 79 volume-title: The Cochrane Library, Issue 4 year: 2006 ident: e_1_2_6_10_2 – ident: e_1_2_6_16_2 doi: 10.1007/s10156-005-0407-X – ident: e_1_2_6_32_2 doi: 10.1111/j.1523-5378.2007.00497.x – ident: e_1_2_6_6_2 doi: 10.1358/mf.2005.27.5.896760 – ident: e_1_2_6_4_2 doi: 10.1111/j.1523-5378.2007.00538.x – ident: e_1_2_6_33_2 doi: 10.1046/j.1365-2036.2003.01395.x – ident: e_1_2_6_45_2 doi: 10.1111/j.1365-2036.2004.02274.x – ident: e_1_2_6_9_2 doi: 10.1080/00365529950173627 – ident: e_1_2_6_7_2 doi: 10.3168/jds.S0022-0302(04)73549-3 – ident: e_1_2_6_13_2 doi: 10.1111/j.1365-2036.2006.02851.x – volume: 9 start-page: 576 year: 2004 ident: e_1_2_6_22_2 article-title: Suppressive effect of bovine lactoferrin against Helicobacter pylori publication-title: Helicobacter – ident: e_1_2_6_14_2 doi: 10.1016/j.dld.2005.01.017 – ident: e_1_2_6_8_2 doi: 10.1007/BF02490180 – ident: e_1_2_6_41_2 doi: 10.1111/j.1365-2672.1994.tb03065.x – ident: e_1_2_6_42_2 doi: 10.1111/j.1365-2036.2006.03179.x – volume: 9 start-page: 568 year: 2004 ident: e_1_2_6_23_2 article-title: Efficacy of bovine lactoferrin for Helicobacter pylori eradication: results of a multicenter study publication-title: Helicobacter – ident: e_1_2_6_26_2 doi: 10.1111/j.1572-0241.2007.01514_1.x – volume: 145 start-page: 49 year: 2006 ident: e_1_2_6_17_2 article-title: Bovine lactoferrin added to triple therapy increased Helicobacter pylori eradication rate publication-title: ACP J Club doi: 10.7326/ACPJC-2006-145-2-049 – ident: e_1_2_6_46_2 doi: 10.1046/j.1365-2036.2001.00923.x – ident: e_1_2_6_34_2 – ident: e_1_2_6_36_2 doi: 10.1023/A:1026675916421 – volume: 145 start-page: 49 year: 2006 ident: e_1_2_6_19_2 article-title: Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study publication-title: ACP J Club doi: 10.7326/ACPJC-2006-145-2-049 – volume: 1540 start-page: 12 year: 2006 ident: e_1_2_6_20_2 article-title: Adding bovine lactoferrin to triple therapy in patients with Helicobacter pylori infection increases eradication rates publication-title: Inpharma Wkly – ident: e_1_2_6_29_2 doi: 10.1016/j.dld.2007.05.021 – ident: e_1_2_6_11_2 doi: 10.1002/9780470693926.ch5 – ident: e_1_2_6_12_2 doi: 10.1016/S1590-8658(03)00409-2 – volume: 13 start-page: CR187 year: 2007 ident: e_1_2_6_15_2 article-title: Effect of lactoferrin supplementation on the effectiveness and tolerability of a 7‐day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection publication-title: Med Sci Monit – ident: e_1_2_6_31_2 doi: 10.1111/j.1572-0241.2007.01085.x – volume: 1592 start-page: 10 year: 2007 ident: e_1_2_6_18_2 article-title: The addition of lactoferrin and probiotics to standard triple therapy may be beneficial in patients with Helicobacter pylori infections publication-title: Inpharma Wkly
SSID	ssj0006702
Score	2.1248589
SecondaryResourceType	review_article
Snippet	Summary Background Several randomized‐controlled trials (RCTs) have sought to determine the efficacy of bovine lactoferrin in Helicobacter pylori eradication... Background Several randomized‐controlled trials (RCTs) have sought to determine the efficacy of bovine lactoferrin in Helicobacter pylori eradication with... Several randomized-controlled trials (RCTs) have sought to determine the efficacy of bovine lactoferrin in Helicobacter pylori eradication with equivocal... SummaryBackgroundSeveral randomized-controlled trials (RCTs) have sought to determine the efficacy of bovine lactoferrin in Helicobacter pylori eradication...
SourceID	proquest pubmed pascalfrancis crossref wiley
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	720
SubjectTerms	Anti-Bacterial Agents - therapeutic use Bacterial diseases Bacterial diseases of the digestive system and abdomen Biological and medical sciences Dietary Supplements Digestive system Gastroenterology. Liver. Pancreas. Abdomen Helicobacter Infections - drug therapy Helicobacter pylori Helicobacter pylori - drug effects Human bacterial diseases Humans Infectious diseases Lactoferrin - therapeutic use Medical sciences Pharmacology. Drug treatments Randomized Controlled Trials as Topic
Title	Meta‐analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication
URI	https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2036.2009.03934.x https://www.ncbi.nlm.nih.gov/pubmed/19183156 https://www.proquest.com/docview/20545100 https://www.proquest.com/docview/733320688
Volume	29
WOSCitedRecordID	wos000263908900003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1365-2036 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0006702 issn: 0269-2813 databaseCode: WIN dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1365-2036 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0006702 issn: 0269-2813 databaseCode: DRFUL dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1fS9xAEB_aU0pBbG2tRttzH_qaks0m2axvoh4t6CGi9t7C7mYDguSOu1Pat36EfkY_iTPJ3rUBBSmFPCSQTTY7_2cnvwH4nEnussrwUFkuwiSt0lBzwUOXciGtiCvTJPSvTuRwmI9G6szXP9G_MC0-xDLhRpLR6GsScG1mXSFvKrRQBXvYSaFE8gX9yZUY2TjtwcrR-eDyZKmXM9lUIGLQocI456Jb1_PoszrGam2iZ7huVdvw4jGPtOvgNhZq8OZ_fttbWPd-KjtoGWsDXrj6Hbw69Tvx7-H81M31_a_f2oOa7DNHYBTa_mTjihnKUzh2Q818KsJ-rBkeaOKQ70yDD80mlCm4Zm6qS5823ITLwfHF4dfQ92cILeHShyZDgXaqFNSxmJu8zG1uJbdEfJkojbFaquMIX50po5WNbFKih-VKkZSZKKX4AL16XLttYFnC89K4KiW4Oe2kcsZEOklVakWlIx2AXBCisB68nHpo3BR_BTG4ZAUtGbXWVEWzZMWPAPhy5KQF8HjGmH6H1suBaOfRv4mSAPYWxC9QHGmPRddufDvDx6BLyqMoAPbEHVIIEVOrnwC2Wrb5My-FChYD6gCyhjuePeHi4OyCznb-deAuvF5sk0X8I_Tm01v3CVbt3fx6Nu3DSznK-16e8Or7t-ED_14c5Q
linkProvider	Wiley-Blackwell
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9wwEB1KWtpCSD-SNm7ajQ69Olgr2bJyW0pCQneXULZJbkaSZQgE77K7Ke2tP6G_sb8kM7J3G0MKoRR88MEjy5JGejOS3wP4mCnus8ryWDsuYplWaWy44LFPuVBO9CsbEvrnQzUe55eX-qyVA6J_YRp-iHXCjTwjzNfk4JSQ7np5OKKFc3DLOym0kAcIKB9LxB2k43BxOl5Py5kKBxAx5tBxP-eie6zn3pI6a9XmzCyw2apG7-I-QNrFt2GBOn7xXz_tJWy1OJUNmoH1Ch75-jU8HbU78dvwZeSX5vfPX6YlNTlknsgojPvBphWzlKfw7JrEfCrifqwZXrjE4bizgR-azShTcMX83JRt2nAHvh4fTT6dxK0-Q-yIlz62GTq016UgxWJu8zJ3uVPcUecrqQ3GaqnpJ_jqTFujXeJkiQjLl0KWmSiVeAMb9bT2u8AyyfPS-iolujnjlfbWJkamOnWiMomJQK16onAteTlpaFwXd4IYbLKCmoykNXURmqz4HgFfW84aAo8H2PQ6nb02xHUe8U0iI9hf9X6B7kh7LKb205sFFoOQlCdJBOwvTyghRJ-kfiJ424ybP_XSOMFiQB1BFobHgytcDM4mdPfuXw334dnJZDQshqfjz3vwfLVllvD3sLGc3_gP8MR9W14t5r3gVLcbhx2w
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1ba9RAFD7IVoog3qvR2s6Dr5HMTpLJ9K3YLorbZSmt9C3MFQolu-xuRd_8Cf5Gf0nPSWZXAxWKCHnIQ2YymTPnOpPvA3hXSu7LYHiqLBdpXoQi1Vzw1BdcSCuGwbQF_S9jOZlUFxdqGumA6F-YDh9iU3AjzWjtNSm4n7vQ1_L2iBba4Ig7KZTI32NAuZUTp8wAto5OR-fjjWEuZXsEEbMOlQ4rLvoHe27tq-etHs71EicudIwXt4Wk_Qi3dVGjx__1457AoxipssNuaT2Fe755BtsncS_-OZye-JX-9eOnjrAmB8wTHIW239ksMEOVCs-uiM4nEPpjw_BCJ4crz7QI0WxOtYJL5hfaxcLhCzgfHZ99-JhGhobUEjJ9akpUaa-cIM5ibipX2cpKbkn8Mlcas7VCDzN8damMVjazucMYyzuRu1I4KXZg0Mwa_wpYmfPKGR8KApzTXipvTKZRkIUVQWc6AbmWRG0jfDmxaFzVf6QxOGU1TRmRa6q6nbL6WwJ803LeQXjcoc1eT9ibhujpMcLJ8gT219KvUSFpl0U3fna9xG4wKOVZlgD7yxNSCDEksp8EXnbr5ve4FJpYTKkTKNvlcecB14fTM7p7_a8N92F7ejSqx58mn9_Ag_WeWcZ3YbBaXPu3cN9-XV0uF3tRq24AC0ceWQ
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Meta%E2%80%90analysis%3A+efficacy+of+bovine+lactoferrin+in+Helicobacter+pylori+eradication&rft.jtitle=Alimentary+pharmacology+%26+therapeutics&rft.au=SACHDEVA%2C+A.&rft.au=NAGPAL%2C+J.&rft.date=2009-04-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=0269-2813&rft.eissn=1365-2036&rft.volume=29&rft.issue=7&rft.spage=720&rft.epage=730&rft_id=info:doi/10.1111%2Fj.1365-2036.2009.03934.x&rft.externalDBID=10.1111%252Fj.1365-2036.2009.03934.x&rft.externalDocID=APT3934
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0269-2813&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0269-2813&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0269-2813&client=summon